Nadunolimab
- Generic Name
- Nadunolimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- ND296JF21I
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06548230
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Cantargia AB
- Target Recruit Count
- 116
- Registration Number
- NCT05181462
- Locations
- 🇪🇸
Hospital Universitario Virgen de las Nieves, Granada, Andalucía, Spain
🇪🇸Hospital Universitario Clinico San Cecilio, Granada, Andalucía, Spain
🇪🇸Complejo Hospitalario de Jaén, Jaén, Andalucía, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath